Recombinant Human CCL23/MPIF-1
| Code | Size | Price |
|---|
| LEI-M180-25ug | 25 ug | £398.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Shipping:
Ambient
Storage:
The lyophilized protein should be stored desiccated at -20°C. The reconstituted protein can be stored for at least one week at 4°C. For long-term storage of the reconstituted protein aliquot into working volumes and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Format:
This recombinant protein was lyophilized from a 0.2 um filtered solution in 30% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid (TFA).
Formulation:
This recombinant protein was lyophilized from a 0.2 um filtered solution in 30% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid (TFA).
Long Description:
CCL23, also known as MIP-3, is a small cytokine belonging to the CC chemokine family (1). It is most closely related to CCL15. CCL23 is predominantly expressed in lung and liver tissue but is also found in bone marrow, placenta and cells of the myeloid lineage (2). CCL23 induces endothelial cell migration and tube formation. It also enhances the expression of MMP-2 mRNA and protein levels in endothelial cells. CCL23 may play a direct role in angiogenesis (3). It is highly chemotactic for resting T cells and monocytes and slightly chemotactic for neutrophils and has also been attributed to an inhibitory activity on hematopoietic progenitor cells (2). CCL23 has been shown to suppress the low proliferative potential colony-forming cells that give rise to granulocyte and monocyte lineages.
NCBI Gene:
6368
Purity:
>97% by SDS-PAGE and analyzed by silver stain.
Target:
CCL23
References
1. Huang, SA. et al. (2007) J Experimental Hematol. 15: 496
2. Woisetschl?ger, M. et al. (2007) J Immunol 178: 4335
3. Kim, J. et al. (2006) Biochemical and biophysical res communications 340:498
Related Products
| Product Name | Product Code | Supplier | Recombinant Human CCL23 (aa 46-137) | LEI-C1342 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human Chemokine Ligand 23 | LEI-C1412 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human CCL23-Biotin | LEI-C1493 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human CCL23-Biotin | LEI-C1506 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Human CCL23 | LEI-M1236 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human CCL23 | LEI-M181 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human CCL23-Biotin | LEI-M196 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||